About Us

MABT was founded in 2011 with the simple goal of making a meaningful difference on the lives of patients, families and communities worldwide. We are especially excited about our work on neurodegenerative conditions such as Alzheimer’s, Parkinson’s and ALS.

Mid-Atlantic BioTherapeutics is committed to pushing the boundaries of scientific understanding and therapeutic efficacy to address an unmet need for diseases that are hard to treat. By leveraging the power of biotechnology and artificial intelligence, we believe that we may be able to treat currently incurable diseases.

MABT has multiple novel proprietary technologies that we test for the goal of having a profound impact on hard to treat diseases. We were even the first company ever to qualify for Orphan Drug Designation for Rabies, the world’s most deadly disease with our proprietary technology platform Immunotherapy, IMT504.

Everyday, MABT works towards a brighter future. We are concentrating on the clinical development and commercialization of treatments for hard to treat disorders, especially neurological diseases.

Press Play

OUR CEO

Welcome to Mid-Atlantic BioTherapeutics (MABT), where innovation meets compassion in the pursuit of transforming healthcare. At MABT, we are dedicated to advancing cutting-edge therapies for some of the most challenging neurological and infectious diseases facing society today.

At the heart of our innovation lies our advanced scientific approach. MABT combines deep expertise in biotechnology with state-of-the-art AI-driven computational methods to accelerate drug discovery and development. This interdisciplinary approach allows us to identify promising therapeutic targets more efficiently and design optimized therapies with enhanced precision.

This is not just science; it’s a journey of hope, compassion, and relentless dedication. I invite you to join us on this incredible journey.

-Dr. David Horn

News

Mid-Atlantic BioTherapeutics, Inc. Launches $5 Million Regulation D 506(c) Funding Round to Support Clinical Program Acceleration and Expand the Company’s Global Reach and Market Presence

DOYLESTOWN, Pa., Oct. 15, 2024 /PRNewswire/ — Mid-Atlantic BioTherapeutics, Inc. (the “Company“), a clinical-stage biotechnology company specializing in cutting-edge immunotherapies and central nervous system (“CNS“) disorder treatments, today announced the commencement of a fundraising round …

CONTACT

Please enable JavaScript in your browser to complete this form.
Name

Mid-Atlantic BioTherapeutics
3805 Old Easton Road
Doylestown, PA 18902
USA